Cue Biopharma Announces FDA Acceptance of IND for Lead Immuno-oncology Candidate, CUE-101, in Treatment of HPV-driven Cancers

NEXT STORY
BeyondSpring’s Rationale for the Plinabulin-Neulasta Combination for Neutropenia Prevention Accepted as Abstracts at 2019 ASCO Annual Meeting
PREV STORY
Résultats positifs de la plateforme ciblée en oncologie de Theratechnologies présentés en ligne à ASCO
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Symphony Health Solutions Announces New Market Access Audit Powered by IDV®

CONSHOHOCKEN, Pa., March 29, 2016 (GLOBE NEWSWIRE) -- Symphony Health Solutions, a provider of ...

author_avatar
NASDAQ Market News

Leap Therapeutics To Present at 19th Annual BIO CEO & Investor Conference

CAMBRIDGE, Mass., Feb. 09, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology ...

author_avatar
NASDAQ Market News

RedHill Biopharma Announces Enrollment of Last Patient in the BEKINDA® Phase II Study for IBS-D

Top-line results are expected in the third quarter of 2017  The randomized, double-blind, placebo-controlled Phase ...

author_avatar
NASDAQ Market News